Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab-Reference-Cited by-同舟云学术

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Published:2023-10 Issue: Volume:190 Page:104089
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Debien Veronique,Marta Guilherme Nader,Agostinetto Elisa,Sirico Marianna,Jacobs Flavia,Molinelli Chiara,Moreau Michel,Paesmans Marianne,De Giorgi Ugo,Santoro Armando,Taylor Donatienne,Duhoux François P.,Botticelli Andrea,Barchiesi Giacomo,Speranza Iolanda,Lambertini Matteo,Wildiers Hans,Azambuja Evandro de,Piccart Martine

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. A food and drug administration analysis of survival outcomes comparing the adjuvant paclitaxel and trastuzumab trial with an external control from historical clinical trials;Amiri-Kordestani;Ann. Oncol.,2020

2. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial;Barroso-Sousa;Ann. Oncol.,2019

3. Customizing local and systemic therapies for women with early breast cancer: the St. gallen international consensus guidelines for treatment of early breast cancer 2021;Burstein;Ann. Oncol.,2021

4. ESMO guidelines committee. electronic address: clinicalguidelines@esmo.org early breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up†;Cardoso;Ann. Oncol.,2019

5. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial;Chan;Clin. Breast Cancer,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advancements in Metallic Au- and Ag-Based Chitosan Nanocomposite Derivatives for Enhanced Anticancer Drug Delivery;Molecules;2024-05-19

2. The Sweet and Sour of Glycan Targeting in Cancer;Interdisciplinary Cancer Research;2024